Back
89
54
Day Range
$909.09
$922.15
52-Week Range
$623.78
$1,133.95
Volume
1,603,428
50D / 200D Avg
$1,024.73
/
$892.56
Prev Close
$903.02
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (631 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 42.0 | 0.2 |
| P/B | 32.6 | 3.0 |
| ROE % | 101.4 | 3.6 |
| Net Margin % | 31.7 | 3.8 |
| Rev Growth 5Y % | 23.2 | 9.9 |
| D/E | 1.6 | 0.2 |
Analyst Price Target
Hold
$1,243.95
+35.7%
Low: $985.00
High: $1,350.00
Forward P/E
26.62
Forward EPS
$34.43
EPS Growth (est.)
+0.0%
Est. Revenue
81.69B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$60.97
$56.29 – $66.45
|
126.59B | 3 |
| FY2029 |
$55.40
$51.14 – $60.38
|
117.17B | 3 |
| FY2028 |
$49.21
$42.81 – $55.86
|
106.38B | 9 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-04 | $6.91 | $7.54 | +9.1% |
| 2025-10-30 | $5.69 | $7.02 | +23.4% |
| 2025-08-07 | $5.60 | $6.31 | +12.7% |
| 2025-05-01 | $3.26 | $3.34 | +2.5% |
| 2025-02-06 | $5.03 | $5.32 | +5.8% |
| 2024-10-30 | $1.47 | $1.18 | -19.7% |
| 2024-08-08 | $2.60 | $3.92 | +50.8% |
| 2024-04-30 | $2.46 | $2.58 | +4.9% |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 |
Fyrwald J Erik
Director
|
grant | 10 | $989.12 | $9,891.20 |
| Feb 17, 2026 |
Sulzberger Gabrielle
Director
|
grant | 5 | $1,036.05 | $5,180.25 |
| Feb 16, 2026 |
Brown Adrienne S
EVP, President LLY Imm
|
other | 952 | — | — |
| Feb 9, 2026 |
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
|
grant | 4,163 | $1,044.67 | $4,348,961.21 |
| Feb 9, 2026 |
Jonsson Patrik
EVP & President, LLY Int'l
|
grant | 4,818 | $1,044.67 | $5,033,220.06 |
| Feb 9, 2026 |
Brown Adrienne S
EVP, President LLY Imm
|
grant | 1,196 | $1,044.67 | $1,249,425.32 |
| Feb 9, 2026 |
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
|
grant | 4,866 | $1,044.67 | $5,083,364.22 |
| Feb 9, 2026 |
Montarce Lucas
EVP & CFO
|
grant | 1,365 | $1,044.67 | $1,425,974.55 |
| Feb 9, 2026 |
Ricks David A
President, Chair, and CEO
|
grant | 38,914 | $1,044.67 | $40,652,288.38 |
| Feb 1, 2026 |
Jonsson Patrik
EVP & President, LLY Int'l
|
other | 9,612 | — | — |
| Feb 1, 2026 |
Van Naarden Jacob
EVP,Pres LLY Oncology&HdCorpBD
|
other | 10,125 | — | — |
| Feb 1, 2026 |
Yuffa Ilya
EVP&Pres, LLY USA&Global Capab
|
other | 8,300 | — | — |
| Jan 20, 2026 |
Sulzberger Gabrielle
Director
|
grant | 5 | $1,041.29 | $5,206.45 |
| Dec 15, 2025 |
Fyrwald J Erik
Director
|
grant | 9 | $1,062.19 | $9,559.71 |
| Dec 15, 2025 |
LUCIANO JUAN R
Director
|
grant | 14 | $1,062.19 | $14,870.66 |
| Nov 17, 2025 |
Kaelin William G Jr
Director
|
grant | 215 | $1,021.70 | $219,665.50 |
| Oct 20, 2025 |
Fyrwald J Erik
Director
|
grant | 12 | $808.96 | $9,707.52 |
| Sep 15, 2025 |
LUCIANO JUAN R
Director
|
grant | 20 | $748.19 | $14,963.80 |
| Aug 12, 2025 |
Skovronsky Daniel
EVP, CSO & Pres. LRL & LLY Imm
|
buy | 1,000 | $634.41 | $634,405.00 |
| Aug 12, 2025 |
Sulzberger Gabrielle
Director
|
buy | 117 | $641.18 | $75,018.29 |
Dividend History
7 yr streakYield
0.01%
Payout Ratio
0.26%
Growth (3Y)
15.24%
Growth (5Y)
15.18%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Feb 13, 2026 | Mar 10, 2026 | $1.73 | 0.60% |
| Nov 14, 2025 | Dec 10, 2025 | $1.50 | 0.59% |
| Aug 15, 2025 | Sep 10, 2025 | $1.50 | 0.83% |
| May 16, 2025 | Jun 10, 2025 | $1.50 | 0.74% |
| Feb 14, 2025 | Mar 10, 2025 | $1.50 | 0.64% |
| Nov 15, 2024 | Dec 10, 2024 | $1.30 | 0.70% |
| Aug 15, 2024 | Sep 10, 2024 | $1.30 | 0.54% |
| May 15, 2024 | Jun 10, 2024 | $1.30 | 0.62% |
| Feb 14, 2024 | Mar 08, 2024 | $1.30 | 0.62% |
| Nov 14, 2023 | Dec 08, 2023 | $1.13 | 0.74% |
| Aug 14, 2023 | Sep 08, 2023 | $1.13 | 0.81% |
| May 12, 2023 | Jun 09, 2023 | $1.13 | 0.97% |
| Feb 14, 2023 | Mar 10, 2023 | $1.13 | 1.17% |
| Nov 14, 2022 | Dec 09, 2022 | $0.98 | 1.10% |
| Aug 12, 2022 | Sep 09, 2022 | $0.98 | 1.23% |
| May 13, 2022 | Jun 10, 2022 | $0.98 | 1.26% |
| Feb 14, 2022 | Mar 10, 2022 | $0.98 | 1.50% |
| Nov 12, 2021 | Dec 10, 2021 | $0.85 | 1.31% |
| Aug 12, 2021 | Sep 10, 2021 | $0.85 | 1.25% |
| May 13, 2021 | Jun 10, 2021 | $0.85 | 1.63% |
Key Takeaways
Revenue grew 23.17% annually over 5 years — strong growth
Earnings grew 94.88% over the past year
ROE of 101.35% indicates high profitability
Net margin of 31.66% shows strong profitability
Generating 8.97B in free cash flow
P/E of 41.95 — premium valuation
Growth
Revenue Growth (5Y)
23.17%
Revenue (1Y)44.70%
Earnings (1Y)94.88%
FCF Growth (3Y)N/A
Quality
Return on Equity
101.35%
ROIC32.26%
Net Margin31.66%
Op. Margin45.56%
Safety
Debt / Equity
1.60
Current Ratio1.58
Interest Coverage37.34
Valuation
P/E Ratio
41.95
Forward P/E26.62
P/B Ratio32.63
EV/EBITDA30.35
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 44.70% | Revenue Growth (3Y) | 38.20% |
| Earnings Growth (1Y) | 94.88% | Earnings Growth (3Y) | 98.45% |
| Revenue Growth (5Y) | 23.17% | Earnings Growth (5Y) | 38.67% |
| Profitability | |||
| Revenue (TTM) | 65.18B | Net Income (TTM) | 20.64B |
| ROE | 101.35% | ROA | 18.35% |
| Gross Margin | 83.79% | Operating Margin | 45.56% |
| Net Margin | 31.66% | Free Cash Flow (TTM) | 8.97B |
| ROIC | 32.26% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1.60 | Current Ratio | 1.58 |
| Interest Coverage | 37.34 | ||
| Dividends | |||
| Dividend Yield | 0.01% | Payout Ratio | 0.26% |
| Dividend Growth (3Y) | 15.24% | Dividend Growth (5Y) | 15.18% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 41.95 | Forward P/E | 26.62 |
| P/B Ratio | 32.63 | P/S Ratio | 13.28 |
| PEG Ratio | 0.49 | Forward PEG | N/A |
| EV/EBITDA | 30.35 | Fwd EV/EBITDA | 34.36 |
| Forward P/S | 10.60 | Fwd Earnings Yield | 3.76% |
| FCF Yield | 1.04% | ||
| Market Cap | 865.85B | Enterprise Value | 901.19B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 65.18B | 45.04B | 34.12B | 28.54B | 28.32B |
| Net Income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B |
| EPS (Diluted) | 22.95 | 11.71 | 5.80 | 6.57 | 5.85 |
| Gross Profit | 54.62B | 36.62B | 27.04B | 21.91B | 21.01B |
| Operating Income | 29.70B | 17.50B | 10.79B | 8.65B | 7.93B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 112.48B | 78.71B | 64.01B | 49.49B | 48.81B |
| Total Liabilities | 85.94B | 64.44B | 53.14B | 38.71B | 39.65B |
| Shareholders' Equity | 26.54B | 14.19B | 10.77B | 10.65B | 8.98B |
| Total Debt | 42.50B | 33.64B | 25.23B | 16.24B | 16.88B |
| Cash & Equivalents | 7.16B | 3.27B | 2.82B | 2.07B | 3.82B |
| Current Assets | 55.63B | 32.74B | 25.73B | 18.03B | 18.45B |
| Current Liabilities | 35.23B | 28.38B | 27.29B | 17.14B | 15.05B |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#14 of 158
Custom
Full Throttle
#45 of 148
Recent Activity
Entered
Growth Investing (Philip Fisher)
Mar 24, 2026
Entered
Full Throttle
Mar 24, 2026